Sumary of Psoriatic Arthritis Research: News You Can Use From ACR 2021:
- An estimated 1.5 million Americans are affected by this rheumatological disease, which strikes about one-third of all people who have psoriasis.
- One limitation of these drugs, however, is that they can increase the risk of infection.
- Researchers from Boston University Medical Center decided to see if infection rates have indeed gone up in recent years, a time when the use of biologics has grown.
- With infection rates declining, people can feel more comfortable knowing that the increasing use of biologics has not translated into a corresponding growth in serious infections.
- RELATED: Remote Fitness Classes Can Improve Pain, Stiffness, and Fatigue in People With Many Types of Arthritis 2. Active Psoriatic Arthritis Improves With the Monoclonal Antibody Drug RisankizumabWhat’s New Two studies presented at the conference found that risankizumab (Skyrizi) is effective against PsA.
- In the randomized clinical trials, considered the best way to evaluate a drug, people with PsA reduced the severity of their disease by taking this medication.
- One study, known as KEEPsAKE 2, involved 443 adults with active cases of PsA who had not been sufficiently helped by prior disease modifying drugs (DMARD) or one or two biologic therapies.
- More patients reported an improvement in their symptoms after taking risankizumab, regardless of what drugs they might have taken in the past.